Yükleniyor... / Loading...
This study examined the combination of the drugs RMC-4630 and Sotorasib in patients with KRASG12C-mutated non-small cell lung cancer whose prior standard therapies had failed. It enrolled patients aged 18 and older with locally advanced or metastatic disease who had received up to three prior lines of therapy. It was a Phase 2 study and is completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
+20
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Subject must be ≥18 years of age. * Subject must have pathologically documented, locally advanced or metastatic KRASG12C NSCLC (not amenable to curative surgery) that has progressed on prior standard therapies (no more than 3 prior lines of therapies are allowed) Exclusion Criteria * Primary central nervous system (CNS) tumors * Known or suspected leptomeningeal or brain metastases or spinal cord compression * Clinically significant cardiac disease * Known impairment of GI function that would alter the absorption * Active autoimmune disease requiring systemic treatment within past 2 years * History of severe allergic reactions to any of the study intervention components * Major surgical procedures within 28 days or non-study-related minor procedures within 7 days of treatment. * Prior therapy with KRASG12C inhibitor and/or SHP2 inhibitor